N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 物理性質
- 融点 :
- 67-69℃
- 比重(密度) :
- 1.205±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- under inert gas (nitrogen or Argon) at 2–8 °C
- 酸解離定数(Pka):
- 13.36±0.50(Predicted)
安全性情報
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 価格
もっと(9)
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01MAS125500 |
N-((3R,4R)-1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
477600-73-0 |
1g |
¥351900 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQV-1923 |
N-((3R,4R)-1-Benzyl-4-methylpiperidin-3-yl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine |
477600-73-0 |
1g |
¥40000 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQV-1923 |
N-((3R,4R)-1-Benzyl-4-methylpiperidin-3-yl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine |
477600-73-0 |
5g |
¥120000 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01MAS125500 |
N-((3R,4R)-1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
477600-73-0 |
250mg |
¥144900 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01MAS125500 |
N-((3R,4R)-1-Benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
477600-73-0 |
500mg |
¥273700 |
2024-03-01 |
購入 |
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 化学特性,用途語,生産方法
使用
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine is an important pharmaceutical intermediate used for the synthesis of tofacitinib. Tofacitinib is a Janus kinase (JAK) inhibitor drug used to treat rheumatoid arthritis and psoriatic arthritis.
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 上流と下流の製品情報
原材料
準備製品
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 生産企業
Global( 170)Suppliers
477600-73-0()キーワード:
- 477600-73-0
- 7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-
- 1H-Pyrrolo[2,3-d]pyriMidin-4-aMine,N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-
- Tasocitinib Intermediate
- -1-Benzyl-4-methylpiperidin-3-yl)
- N-((3R,4R)
- Tofacitinib impurity 6/N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- Tofacitinib-10
- (3R, 4R)-(1-benzyl-4-methyl-piperidin-3-yl) -methyl- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -amine
- N-[(3R,4R)-1-benzyl-4-methyl-3-piperidyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- Tofacitib impurity TZ4
- 7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]- ISO 9001:2015 REACH
- 1H-Pyrrolo[2,3-d]pyrimidin-4-amine,N-methyl-N-[(3R,4R)-4-met...
- Azilsartan medoxomil impurity344
- N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmetChemicalbookhyl)-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- Des-(N-oxopropanenitrile)-N-methylbenzyl
- N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- N-((3R,4R)-1-BENZYL-4-METHYLPIPERIDIN-3-YL)-N-METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-
- Tofatinib Impurity 2
- N-((3R,4R)-1-benzyl-4-Methylpiperidin-3-yl)-N-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine